Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1

Molecular Cancer Therapeutics

Volumn 7, Issue 5, 2008, Pages 1246-1250

  Gao, Rui ^a,b   Price, Douglas K ^a   Sissung, Tristan ^a   Reed, Eddie ^c   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GENOMIC DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; ERCC2 PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

AFRICAN AMERICAN; ARTICLE; DNA DETERMINATION; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; CAUCASIAN; DNA REPAIR; ETHNOLOGY; EUROPE; GENETICS; UNITED STATES;

AFRICAN AMERICANS; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; HUMANS; POLY(ADP-RIBOSE) POLYMERASES; POLYMORPHISM, GENETIC; UNITED STATES; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 49849094237     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2206     Document Type: Article

References (53)

1. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 2005;11:6100-2.
2. Reed E. ERCC1 measurements in clinical oncology. N Engl J Med 2006;355:1054-5.
3. Mu D, Hsu DS, Sancar A. Reaction mechanism of human DNA repair excision nuclease. J Biol Chem 1996;271:8285-94.
4. Mu D, Park CH, Matsunaga T, Hsu DS, Reardon JT, Sancar A. Reconstitution of human DNA repair excision nuclease in a highly defined system. J Biol Chem 1995;270:2415-8.
5. van Duin M, de Wit J, Odijk H, et al. Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell 1986;44:913-23.
6. van Duin M, Koken MH, van den Tol J, et al. Genomic characterization of the human DNA excision repair gene ERCC-1. Nucleic Acids Res 1987;15:9195-213.
7. Hoeijmakers JH, Egly JM, Vermeulen W. TFIIH: a key component in multiple DNA transactions. Curr Opin Genet Dev 1996;6:26-33.
8. Sung P, Bailly V, Weber C, Thompson LH, Prakash L, Prakash S. Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature 1993;365:852-5.
9. Booton R, Ward T, Heighway J, et al. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer 2006;106:2421-7.
10. Su D, Ma S, Liu P, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 2007;36:281-8.
11. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998;24:331-44.
12. Reed E. Nucleotide excision repair and anti-cancer chemotherapy. Cytotechnology 1998;27:187-201.
13. Lunn RM, Helzlsouer KJ, Parshad R, et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000;21:551-5.
14. Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007;18:522-8.
15. Park DJ, Zhang W, Stoehlmacher J, et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003;1:162-6.
16. Kang S, Ju W, Kim JW, et al. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 2006;38:320-4.
17. Sakano S, Wada T, Matsumoto H, et al. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br J Cancer 2006;95:561-70.
18. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001;61:8654-8.
19. Kaina B, Christmann M. DNA repair in resistance to alkylating anticancer drugs. Int J Clin Pharmacol Ther 2002;40:354-67.
20. Ladiges WC. Mouse models of XRCC1 DNA repair polymorphisms and cancer. Oncogene 2006;25:1612-9.
21. El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW. A requirement for PARP1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res 2003;31:5526-33.
22. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977;197:165-7.
23. Perez E, Muss HB. Optimizing adjuvant chemotherapy in early-stage breast cancer. Oncology (Huntingt) 2005;19:1759-67; discussion 68, 72-4, 77-8.
24. Hotta K, Matsuo K, Kiura K, Ueoka H, Tanimoto M. Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell lung cancer. Curr Opin Oncol 2006;18:144-50.
25. Goldberg RM. Therapy for metastatic colorectal cancer. Oncologist 2006;11:981-7.
26. Alexander D, Chatla C, Funkhouser E, Meleth S, Grizzle WE, Manne U. Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinoma. Cancer 2004;101:66-76.
27. Vinson RK, Hales BF. Expression of base excision, mismatch, and recombination repair genes in the organogenesis-stage rat conceptus and effects of exposure to a genotoxic teratogen, 4-hydroperoxycyclophosphamide. Teratology 2001;64:283-91.
28. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74.
29. Yu JJ, Mu C, Lee KB, et al. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res 1997;382:13-20.
30. Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005;11:6212-7.
31. Zhou W, Liu G, Park S, et al. Gene-smoking interaction associations for the ERCC1 polymorphisms in the riskof lung cancer. Cancer Epidemiol Biomarkers Prev 2005;14:491-6.
32. Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001;61:1354-7.
33. Allan JM, Smith AG, Wheatley K, et al. Genetic variation in XPD predicts treatment outcome and riskof acute myeloid leukemia following chemotherapy. Blood 2004;104:3872-7.
34. Yin J, Vogel U, Ma Y, Guo L, Wang H, Qi R. Polymorphism of the DNA repair gene ERCC2 Lys751Gln and riskof lung cancer in a northeastern Chinese population. Cancer Genet Cytogenet 2006;169:27-32.
35. King CR, Yu J, Freimuth RR, McLeod HL, Marsh S. Interethnic variability of ERCC2 polymorphisms. Pharmacogenomics J 2005;5:54-9.
36. Chung HH, Kim MK, Kim JW, et al. XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. Gynecol Oncol 2006;103:1031-7.
37. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594-601.
38. Quintela-Fandino M, Hitt R, Medina PP, et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 2006;24:4333-9.
39. Duell EJ, Holly EA, Bracci PM, Wiencke JK, Kelsey KT. A population-based study of the Arg399Gln polymorphism in X-ray repair cross-complementing group 1 (XRCC1) and riskof pancreatic adenocarcinoma. Cancer Res 2002;62:4630-6.
40. Duell EJ, Millikan RC, Pittman GS, et al. Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol Biomarkers Prev 2001;10:217-22.
41. Wang ZH, Miao XP, Tan W, Zhang XR, Xu BH, Lin DX. Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer. Ai Zheng 2004;23:865-8.
42. Wang XG, Wang ZQ, Tong WM, Shen Y. PARP1 Val762Ala polymorphism reduces enzymatic activity. Biochem Biophys Res Commun 2007;354:122-6.
43. Lockett KL, Hall MC, Xu J, et al. The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res 2004;64:6344-8.
44. Hao B, Wang H, Zhou K, et al. Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res 2004;64:4378-84.
45. Zhang X, Miao X, Liang G, et al. Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res 2005;65:722-6.
46. Boyer-Chammard A, Taylor TH, Anton-Culver H. Survival differences in breast cancer among racial/ethnic groups: a population-based study. Cancer Detect Prev 1999;23:463-73.
47. Shen Y, Dong W, Esteva FJ, Kau SW, Theriault RL, Bevers TB. Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M. D. Anderson Cancer Center? Breast Cancer Res Treat 2007;102:347-56.
48. Dignam JJ. Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women. J Natl Cancer Inst Monogr 2001;103:36-43.
49. Thatai LC, Banerjee M, Lai Z, Vaishampayan U. Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancer. Urology 2004;64:738-43.
50. Robbins AS, Yin D, Parikh-Patel A. Differences in prognostic factors and survival among White men and Blackmen with prostate cancer, California, 1995-2004. Am J Epidemiol 2007;166:71-8.
51. Gadgeel SM, Kalemkerian GP. Racial differences in lung cancer. Cancer Metastasis Rev 2003;22:39-46.
52. Dignam JJ, Ye Y, Colangelo L, et al. Prognosis after rectal cancer in Blacks and Whites participating in adjuvant therapy randomized trials. J Clin Oncol 2003;21:413-20.
53. Mayberry RM, Coates RJ, Hill HA, et al. Determinants of Black/White differences in colon cancer survival. J Natl Cancer Inst 1995;87:1686-93.